Monoamine oxidase inhibitors.
Monoamine oxidase inhibitors offer effective treatment opportunities to an expanded range of depressed and anxious patients, particularly those with atypical depression. The use of these drugs requires heightened physician awareness and patient education, but the risks are less pronounced than was previously thought. Hypotension is the main side effect. Hypertensive reactions can be avoided by strictly proscribing congestion of MAO inhibitors with indirect-action sympathomimetic substances that occur in certain drugs, foods and beverages.
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy*; D001342:Autonomic Nervous System Diseases / Q000139:chemically induced; D001835:Body Weight / Q000187:drug effects; D003863:Depression / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005502:Food; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000506:poisoning / Q000627:therapeutic use*; D010624:Phenelzine / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine